Giant prolactinoma, germline BRCA1 mutation, and depression: A case report 11 Medical and Health Sciences 1103 Clinical Sciences 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

• Tipo: Artigo em Revista Científica Internacional
• Data: 2018

Autores

Bettencourt Silva, R (Autor) Outra; Queirós, J (Autor) Outra; Pereira, J (Autor) Outra; Carvalho, Davide (Autor) FMUP

Revista

Título: Journal of Medical Case Reports

Vol. 12

ISSN: 1752-1947

Editora: Springer Nature

Indexação

Scopus - 0 Citações

Outras Informações

ID Authenticus: P-00Q-0QA

DOI: 10.1186/s13256-018-1890-x

Abstract (EN): Background: Giant prolactinomas are very rare pituitary tumors that may exhibit an aggressive behavior and present with a life-threatening condition. Case presentation: A 25-year-old white woman was admitted to our hospital with a headache, psychomotor retardation, reduced vision, and loss of autonomy in daily activities. Her past medical history was significant for having oligomenorrhea and a depressive syndrome since her mother's death. She also had a breast cancer gene 1 (BRCA1) mutation and a family history of breast cancer. She had marked hyperprolactinemia (7615 ng/dL), central hypocortisolism, growth hormone deficiency, and a giant pituitary tumor (52 × 30 × 33 mm) which was shown in magnetic resonance imaging with obstructive hydrocephalus, requiring emergency surgery. Treatment with cabergoline led to a 99.8% reduction in serum prolactin levels and significant tumor shrinkage. Her depressive symptoms progressively improved and psychiatric drugs were withdrawn after 3 months of cabergoline treatment. Currently, she is being followed in Endocrinology, Neurosurgery, and Neurophthalmology out-patient clinics and in a breast cancer unit. Careful monitoring, support, and follow-up will be essential throughout this patient's life. Conclusions: This case is a rare presentation of a giant prolactinoma in a young woman, who presented a life-threatening event. She also had an unexpected association between diseases or symptoms that may have contributed to the delay in diagnosis. Given the concomitant presence of a giant prolactinoma, a BRCA1 mutation, and depressive symptoms, a possible association was hypothesized. The breast cancer risk in a BRCA1 mutation carrier and the possible interference of hyperprolactinemia and life events were also discussed. However this hypothesis requires further investigation. © 2018 The Author(s).

Idioma: Inglês

Tipo (Avaliação Docente): Científica